Beryl Drugs Limited

As of June 30, 2026, Beryl Drugs Limited carries a market capitalization of 112.54M, placing it among publicly traded companies globally. Its enterprise value stands at 112.54M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Beryl Drugs Limited has 5.07M shares outstanding.

As of June 30, 2026, Beryl Drugs Limited trades at a trailing price-to-earnings ratio of 17.42.

As of June 30, 2026, Beryl Drugs Limited trades at an EV/EBITDA multiple of 4.46 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.29 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 112.54M versus a market cap of 112.54M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

Over the twelve months ended June 30, 2026, Beryl Drugs Limited recorded 1.64M in income tax expense. That works out to an effective tax rate of 20.76, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 7.88M, leaving 6.25M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Beryl Drugs Limited's stock has gained approximately 11.61% over the past 52 weeks. The 50-day moving average sits at 23.95, while the 200-day moving average is 22.40.

Over the twelve months ended June 30, 2026, Beryl Drugs Limited generated 213.23M in revenue and converted that into 6.25M in net income, yielding earnings per share of 1.27. EBITDA reached 25.22M, while operating income came in at 10.94M.

Over the twelve months ended June 30, 2026, Beryl Drugs Limited posted a gross margin of 42.92, reflecting its pricing power and cost economics. The operating margin of 5.13 and net profit margin of 2.93 provide insight into operational efficiency.